Viral Hepatitis and Hepatocellular Carcinoma

2009 ◽  
pp. 431-447 ◽  
Author(s):  
Jorge A. Marrero
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis

scholarly journals The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma

2021 ◽  
Author(s):  
Cortlandt M. Sellers ◽  
Johannes Uhlig ◽  
Johannes M. Ludwig ◽  
Jeffrey S. Pollak ◽  
Tamar H. Taddei ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Prognostic Value ◽  
Chronic Viral Hepatitis ◽  
Inflammatory Biomarkers

scholarly journals Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ottovon Bismark Dakurah ◽  
Cynthia Raissa Tchuem Tamandjou ◽  
Moleen Zunza ◽  
Wolfgang Preiser ◽  
Tongai Gibson Maponga
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Web Of Science ◽  
African Continent ◽  
Inclusion Criteria ◽  
Hepatitis D ◽  
The Past ◽  
B Virus

Abstract Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa. Aim The study aimed to systematically summarize the changes in the prevalence of viral hepatitis among HCC patients and the overall effect of the prevalence of viral hepatitis on the incidence of HCC over the past four decades in Africa (1980–2019). Methods A literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980 to 2019. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed. Results A total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63–1.71, p < 0.001), 0.82% (95% CI: 0.45–1.18, p < 0.001), and 3.34% (95% CI: 2.44–4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC decreased by − 0.50% (95% CI: − 0.74 – − 0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased. Conclusion Overall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa. This systematic review is registered with PROSPERO®, number CRD42020169723.

Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

2009 ◽  
Vol 150 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alajos Pár
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

2003 ◽  
Vol 3 (8) ◽  
pp. 1169-1176 ◽  
Author(s):  
G Rasi ◽  
P Pierimarchi ◽  
P Sinibaldi Vallebona ◽  
F Colella ◽  
E Garaci
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma

2000 ◽  
Vol 99 (3) ◽  
pp. 207-214 ◽  
Author(s):  
Michiko OKUBO ◽  
Goshi SHIOTA ◽  
Hironaka KAWASAKI
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Total Mass ◽  
Sandwich Elisa ◽  
Chronic Viral Hepatitis ◽  
Rt Pcr ◽  
Platelet Counts ◽  
Indocyanine Green Test ◽  
Normal Controls

Thrombocytopenia in liver diseases is considered to be due to splenic platelet pooling and accelerated destruction. Since thrombopoietin (TPO), a regulator of thrombopoiesis, is produced mainly in the liver, decreased production of TPO may account for thrombocytopenia in liver diseases. To address this issue, we measured serum TPO, using a sensitive sandwich ELISA, in 108 patients with chronic viral hepatitis, which included chronic hepatitis (CH) and liver cirrhosis (LC), and hepatocellular carcinoma (HCC), and in 29 normal controls. TPO mRNA in 78 liver samples was examined by reverse transcription (RT)-PCR. Platelet counts in CH, LC, HCC and controls were 176±15×109/l, 81±8×109/l, 99±7×109/l and 234±9×109/l respectively. Serum TPO levels in CH, LC and HCC were 2.79±0.4 fmol/ml, 1.49±0.2 fmol/ml and 1.97±0.2 fmol/ml, and were higher than those of controls. Serum TPO levels were positively correlated with prothrombin time and serum albumin (P < 0.05, in each case), and negatively correlated with Indocyanine Green test and Pugh score (P < 0.01 and P < 0.05 respectively). However, RT-PCR and immunohistochemistry showed that expression of TPO mRNA and protein were similar in the different liver diseases, suggesting that serum TPO is a reflection of the total mass of functional liver. Platelet counts were negatively correlated with spleen index, but not with serum TPO. These results suggest that thrombocytopenia in liver disease is not directly associated with serum TPO but is associated with hypersplenism.

Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma

2018 ◽  
Vol 18 (8) ◽  
pp. 713-722 ◽  
Author(s):  
Sreelakshmi Kotha ◽  
ShuetFong Neong ◽  
Keyur Patel
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Serum Biomarkers

scholarly journals Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5867
Author(s):  
Mara Klöhn ◽  
Jil Alexandra Schrader ◽  
Yannick Brüggemann ◽  
Daniel Todt ◽  
Eike Steinmann
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Clinical Evidence ◽  
Hepatitis E ◽  
Clinical Spectrum ◽  
Immunocompromised Patients ◽  
Virus Infections ◽  
The Relationship ◽  
Liver Infection

Hepatitis E virus infections are the leading cause of viral hepatitis in humans, contributing to an estimated 3.3 million symptomatic cases and almost 44,000 deaths annually. Recently, HEV infections have been found to result in chronic liver infection and cirrhosis in severely immunocompromised patients, suggesting the possibility of HEV-induced hepatocarcinogenesis. While HEV-associated formation of HCC has rarely been reported, the expansion of HEV’s clinical spectrum and the increasing evidence of chronic HEV infections raise questions about the connection between HEV and HCC. The present review summarizes current clinical evidence of the relationship between HEV and HCC and discusses mechanisms of virus-induced HCC development with regard to HEV pathogenesis. We further elucidate why the development of HEV-induced hepatocellular carcinoma has so rarely been observed and provide an outlook on possible experimental set-ups to study the relationship between HEV and HCC formation.

scholarly journals Hepatocellular carcinoma (HCC); aetiological considerations

2015 ◽  
Vol 1 (1) ◽  
pp. 18 ◽  
Author(s):  
Omar Abdel-Rahman
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Hepatocellular carcinoma (HCC) is a commonly occurring cancer worldwide. The aetiology of HCC, often associated with different molecular carcinogenic pathways, differs geographically; with chronic viral hepatitis being the main cause in most localities. Different driving mutations resulting from distinct carcinogenic pathways potentially impact the choice of effective therapies for HCC.

scholarly journals Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

2022 ◽  
Vol 23 (1) ◽  
pp. 500
Author(s):  
Francesco Paolo Russo ◽  
Alberto Zanetto ◽  
Elisa Pinto ◽  
Sara Battistella ◽  
Barbara Penzo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Virological Suppression ◽  
Risk Patients ◽  
Related Liver Disease ◽  
Direct Acting ◽  
Cell Signaling Pathways

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in “high-risk” patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient’s risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.

Sign in / Sign up

Export Citation Format

Share Document